COVID-19: combining antiviral and anti-inflammatory treatments.
作者信息
Stebbing Justin, Phelan Anne, Griffin Ivan, Tucker Catherine, Oechsle Olly, Smith Dan, Richardson Peter
机构信息
Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Benevolent AI, London, UK.
出版信息
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
Abstract
摘要
相似文献
1
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
2
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
3
COVID-19: an unexpected indication for anti-rheumatic therapies?
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
4
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Sci Immunol. 2020 May 8;5(47). doi: 10.1126/sciimmunol.abc5367.
5
[Baricitinib in the treatment of SARS-CoV-2 infection].
Rev Esp Quimioter. 2020 Aug;33(4):294-295. doi: 10.37201/req/047.2020. Epub 2020 Jun 25.
6
Baricitinib for COVID-19: a suitable treatment?
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
7
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
8
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.
9
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
10
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
引用本文的文献
1
An Interpretable Deep Learning and Molecular Docking Framework for Repurposing Existing Drugs as Inhibitors of SARS-CoV-2 Main Protease.
Molecules. 2025 Aug 18;30(16):3409. doi: 10.3390/molecules30163409.
2
An In Silico Investigation of Brazilian Green Propolis Extracts as Potential Treatment for COVID-19.
ACS Omega. 2025 Aug 5;10(32):35651-35665. doi: 10.1021/acsomega.5c02121. eCollection 2025 Aug 19.
3
ALBACOVIDIOL Study: Effect of Calcifediol Treatment on Mortality in Patients Hospitalized for COVID-19: A Retrospective Analysis.
Nutrients. 2025 Jun 10;17(12):1968. doi: 10.3390/nu17121968.
4
Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients.
Drug Des Devel Ther. 2025 Jun 9;19:4957-4966. doi: 10.2147/DDDT.S509176. eCollection 2025.
5
Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1.
Front Immunol. 2025 Apr 8;16:1502094. doi: 10.3389/fimmu.2025.1502094. eCollection 2025.
6
Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.
Biomark Res. 2025 Mar 29;13(1):52. doi: 10.1186/s40364-025-00764-4.
7
Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects.
Biosaf Health. 2023 Sep 2;5(5):272-279. doi: 10.1016/j.bsheal.2023.08.003. eCollection 2023 Oct.
8
Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis.
Front Med (Lausanne). 2025 Jan 22;12:1445809. doi: 10.3389/fmed.2025.1445809. eCollection 2025.
9
State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.
Biomedicines. 2024 Dec 13;12(12):2829. doi: 10.3390/biomedicines12122829.
10
Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.
J Int Med Res. 2024 Oct;52(10):3000605241281907. doi: 10.1177/03000605241281907.
本文引用的文献
1
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.
Antiviral Res. 2018 Jul;155:67-75. doi: 10.1016/j.antiviral.2018.05.001. Epub 2018 May 16.
4
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.
5
Planning chemical syntheses with deep neural networks and symbolic AI.
Nature. 2018 Mar 28;555(7698):604-610. doi: 10.1038/nature25978.
6
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.
J Clin Invest. 2017 Apr 3;127(4):1338-1352. doi: 10.1172/JCI89857. Epub 2017 Feb 27.
7
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
Lancet. 2003 May 24;361(9371):1767-72. doi: 10.1016/s0140-6736(03)13412-5.
Zotero 插件